Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

Meet Laurel Crosby, PhD, member of the SGTC Team

On this #OMFScienceWednesday we are pleased to introduce you to Laurel Crosby, PhD, who was the first member of the Stanford Genome Technology Center (SGTC) to join Ron in his quest to understand the molecular basis for ME / CFS. Laurel shared her story with OMF.

Laurel Crosby, PhD, member of the SGTC Team

“My name is Laurel Crosby, PhD, and I’m an Engineering Research Associate with the Stanford Genome Technology Center. My background is in biology, microbial ecology, environmental engineering, and molecular diagnostic technology development.  

I helped Ron Davis build out the laboratory component of the CFS Research Center at Stanford, and my official title is the Director of Innovation. I spend half of my time thinking as a scientist, looking for clues, scouring for new technologies, and identifying ways to improve quality of life for patients and their families.  

I’m focused on the interplay between genetics and environment, especially nutrition, the microbiome, and environmental exposures. My engineering background gives me the ability to look at health as a network of interactions, and I focus on metabolomics and genetics as part of the Multi-Omics component of our research program.  

I’m also currently working on strategies to assess heavy metals exposure, and more precise ways to measure essential trace metals in cells and tissues.

The rest of my time I spend as “the fixer.” I make sure that things get done smoothly and seamlessly, and I support the rest of the ME / CFS research team at SGTC.

For example, when we were hungry for patient samples, I wrote the IRB (Independent Review Board) protocols and set up the phlebotomy services. When I found a promising new technology, I negotiated with companies to provide equipment demonstrations and favorable pricing.

Right now, I’m working on how to provide doctors and patients with access to our precision medicine tools and services. I always try to find a way to make things work and make things less expensive.

In 2012, Ron and I were the only people at the Stanford Genome Technology Center interested in studying ME / CFS, and now we are a bustling center with more than a dozen researchers, several exciting projects, and many domestic and international collaborations.”

Thank you, Laurel, for your courageous, longstanding and unwavering commitment to our quest to help patients return fully to their lives.

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo